Table 2.
SRSF‐1 expression according to IHC score
| SRSF‐1 | |||
|---|---|---|---|
| Negative (n = 180) | Positive (n = 188) | p Value | |
| Age (years), median (IQR) | 76.0 (70.0–79.0) | 67.0 (63.0–72.0) | .82 |
| PSA (ng/ml), median IQR) | 2.05 (0.9–4.27) | 7.8 (5.7–11.6) | <.01 |
| Fasting glucose (mg/dl), median (IQR) | 95.0 (84.0–116.0) | 97.0 (88.0–107.5) | .51 |
| Total cholesterol (mg/dl), median (IQR) | 172.0 (150.0–194.0) | 191.5 (168.0–224.0) | .60 |
| Triglycerides (mg/dl), median (IQR) | 110.0 (69.0–164.0) | 97.0 (66.0–130.0) | .85 |
| Diabetes, n (%) | 38 (21.1) | 27 (14.36) | .09 |
| Group, n (%) | <.01 | ||
| BPH | 64 (35.56) | 35 (18.62) | |
| PC | 116 (64.44) | 153 (81.38) | |
| ISUP Gleason score, n (%) | .04 | ||
| 1 | 42 (36.21) | 34 (22.37) | |
| 2 | 44 (37.93) | 58 (38.16) | |
| 3 | 21 (18.10) | 44 (28.95) | |
| 4 | 3 (2.59) | 10 (6.58) | |
| 5 | 6 (5.17) | 6 (3.95) | |
| Pathological stage, n (%) | .46 | ||
| T2 | 64 (72.41) | 99 (65.79) | |
| T3 | 18 (15.52) | 32 (21.05) | |
| T4 | 14 (12.07) | 20 (13.16) | |
| Classification risk of PC, n (%) | .054 | ||
| Low risk | 50 (43.10) | 45 (29.61) | |
| Intermediate risk | 47 (40.52) | 70 (46.05) | |
| High risk | 19 (16.38) | 27 (24.34) | |
| Ki‐67 positive score, n (%) | 8 (4.44) | 41 (21.81) | <.01 |
| AR positive score, n (%) | 72 (40.0) | 99 (52.66) | <.05 |
| PSMA positive score, n (%) | 55 (30.56) | 91 (48.40) | <.01 |
| PSA positive score, n (%) | 17 (34.0) | 154 (48.43) | .057 |
| IR‐α positive score, n (%) | 103 (57.22) | 143 (76.06) | <.01 |
| IR‐β positive score, n (%) | 5 (2.78) | 17 (9.04) | <.05 |
| IGF‐1R positive score, n (%) | 24 (13.33) | 36 (19.15) | 0.13 |
| MVD, median (IQR) | 32.0 (27.0–38.0) | 88.0 (44.0–111.0) | |
Abbreviations: AR, androgenic receptor; BPH, benign prostatic hyperplasia; IGF‐1R, insulin‐like growth factor‐1 receptor; IQR, interquartile range; IR, insulin receptor; PCa, prostate cancer; PSA, prostate‐specific antigen; PSMA, prostate specific membrane antigen.